Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-07-29
2010-06-01
Gitomer, Ralph (Department: 1657)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S026400
Reexamination Certificate
active
07727972
ABSTRACT:
The present invention relates to a method for determining absorption of cobalamin or analogues thereof in an individual comprising (ii providing two blood samples from said individual, wherein the first sample comprises said individual's blood prior to ingestion by said individual of non-radioactive cobalamin or an analogue thereof and the second sample comprises said individual's blood after said ingestion, (ii) determining the concentration of cobalamin or analogue thereof in the first sample, (iii) determining the concentration of cobalamin or analogue thereof in the second sample by treating complexes of cobalamin or analogue thereof and one or more carrier proteins with one or more enzymes to release cobalamin or analogue thereof from said one or more carrier proteins, and (iv) determining, on the basis of comparison of said concentrations in said two samples, whether said cobalamin or analogue thereof has been absorbed in the blood stream.
REFERENCES:
patent: 3981863 (1976-09-01), Niswender et al.
patent: 5506109 (1996-04-01), Pourfarzaneh et al.
patent: 2004/0268440 (2004-12-01), Berglund et al.
patent: 2006/0166271 (2006-07-01), Berglund et al.
patent: WO 2006010369 (2006-02-01), None
Burger et al., “Human Plasma R-Type Vitamin B12-binding Proteins. I. Isolation and Characterization of Transcobalamin I, Transcobalamin III, and the Normal Granulocyte VitaminB12-Binding Protein,”J. Biol. Chem., 250(19):7700-7706, Oct. 10, 1975.
Carmel, “Vitamin B12-binding Proteins in Serum and Plasma in Various Disorders. Effect of Anticoagulants,”Am. J. Clin. Pathol., 69:317-25, 1978.
Carmel, “R-Binder Deficiency. A Clinically Benign Cause of Cobalamin Pseudodeficiency,”JAMA, 250(14):1886-90, Oct. 14, 1983.
Carmel et al., “Plasma Total Transcobalamin I. Ethnic/Racial Patterns and Comparison With Lactoferrin,”Am. J. Clin. Pathol., 116:576-80, 2001.
Carmel, “Mild Transcobalamin I (Haptocorrin) Deficiency and Low Serum Cobalamin Concentrations,”Clin. Chem., 49(8):1367-74, 2003.
Gimsing et al., “Increased Concentration of Transcobalamin I in a Patient with Metastatic Carcinoma of the Breast,”Scand. J. Haematol., 21:243-49, 1978.
Hall et al., “Improved Method for the Extraction of Vitamin B12from Serum,”J. Lab. Clin. Med. 63(3):517-23, Mar. 1964.
Jørgensen et al., “An Immunoassay Designed to Quantitate Different Molecular Forms of Rat Urinary Epidermal Growth Factor with Equimolar Potency: Application on Fresh Rat Urine,”Scand. J. Clin. Lab. Invest., 56:25-36, 1996.
Lindemans et al., “Application of a Simple Immunoadsorption Assay for the Measurement of Saturated and Unsaturated Transcobalamin II and R-binders,”Clin. Chim. Acta, 132:53-61, 1983.
Lindgren et al., “Holotranscobalamin—a Sensitive Marker of Cobalamin Malabsorption,”Eur. J. Clin. Invest., 29:321-29, 1999.
Morelli et al., “A Radioimmunoassay for the R-Type Binders of Cobalamin,”Clin. Chim. Acta, 77:365-72, 1977.
Nexø et al., “Characterization of a Cobalamin-binding Plasma Protein from a Patient with Hepatoma,”Scand. J. Clin. Lab. Invest., 35:683-90, 1975.
Nexø, “A New Principle in Biospecific Affinity Chromatography Used for Purification of Cobalamin-binding Proteins,”Biochim. Biophys. Acta., 379:189-92, 1975.
Nexø et al., “A Rare Case of Megaloblastic Anaemia Caused by Disturbances in the Plasma Cobalamin Binding Proteins in a Patient with Hepatocellular Carcinoma,”Scand. J. Haematol., 14:320-27, 1975.
Nexø, “Transcobalamin I and other Human R-binders: Purification, Structural, Spectral and Physiological Studies,” FADL's forlag, Copenhagen, 1978.
Nexø, “Cobalamin Binding Proteins,” In: Kräutler, B. et al. (Eds.), “Vitamin B12and B12- Proteins,” Wiley-VCH, 1998.
Nexø et al., “Measurement of Transcobalamin by ELISA,”Clin. Chem., 46(10):1643-49, 2000.
Raven et al., “Extraction of Serum Vitamin B12for Radio-isotopic andLactobacillus leischmanniiAssay,”J. Clin. Path., 28:531-39, 1975.
Sandberg et al., “The Content, Binding, and Forms of Vitamin B12in Milk1-3,”Am. J. Clin. Nutrition, 34:1717-24, Sep. 1981.
Stenman, “Characterization of R-Type Vitamin B12-Binding Proteins by Isoelectric Focusing II. Comparison of Cobalophilin (R Proteins) From Different Sources,”Scand. J. Clin. Lab. Invest., 35:147-55, 1975.
Ulleland et al., “Direct Assay for Cobalamin Bound to Transcobalamin (Holo-transcobalamin) in Serum,”Clin. Chem., 48(3):526-32, 2002.
Yang et al., “The Biochemical and Genetic Basis for the Microheterogeneity of Human R-Type Vitamin B12Binding Proteins,”Blood, 59(4):747-55, Apr. 1982.
Zelder et al., “On the Role of Two Different Cobalt (II) Species in Coenzyme B12-Dependent 2-Methylenegluterate Mutase fromClostridium barkeri,”Biol. Chem. Hoppe-Seyler, 374:85-90, Jan. 1993.
Loikas et al., Blood, vol. 98, No. 11, part 2, pp. 6B -Abstract (2001).
Rothenberg et al., Journal of Laboratory and Clinical Medicine, vol. 103, No. 6, pp. 959-972 (1984).
Ulleland M. et al., Direct Assay for Cobalamin Bound to Transcobalami N (HoloTranscobalami N) I N Serum, Clinical Chemistry, American Association for Clinical Chemistry, Washington, DC, us, vol. 48, No. 3, Mar. (2002).
Zelder O., et al., On the Role of Two Different Cobalt (II) Species in Coenzyme B-12-dependent 2-methyl enegl utarate mutase fromClostridium barkeri, Biological Chemistry Hoppe-Seyler, vol. 374, No. 1, pp. 85-90, (1993).
Office Action, dated Dec. 5, 2008 issued in U.S. Appl. No. 10/549,077.
International Search Report, PCT/DK2005/000512 published in WO 2006/010369 A3 dated Feb. 2, 2006.
Mørkbak Anne Louise
Nexø Ebba
DrugTech Corporation
Gitomer Ralph
LandOfFree
Methods for determining absorption of cobalamin or analogues... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for determining absorption of cobalamin or analogues..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for determining absorption of cobalamin or analogues... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4152201